CRBN and plasma cell myeloma: Further studies reveal that CRBN also directly binds lenalidomide and pomalidomide, and depletion of CRBN blunts the inhibitory effect of lenalidomide and pomalidomide on proliferation of myeloma cells, indicating that CRBN is required for IMiD-mediated anti-proliferation and anti-myeloma activity [84].